Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?

被引:13
作者
Gravas, Stavros [1 ]
Melekos, Michael D. [1 ]
机构
[1] Univ Hosp Larissa, Dept Urol, Larisa 41221, Greece
关键词
anticholinergics; erectile dysfunction; International Prostate Symptom Score; lower urinary tract symptoms; phosphodiesterase type 5 inhibitors; BENIGN PROSTATIC HYPERPLASIA; MALE SEXUAL DYSFUNCTION; OVERACTIVE BLADDER; PHOSPHODIESTERASE-5; INHIBITOR; COMBINATION TREATMENT; ERECTILE DYSFUNCTION; MEN; TADALAFIL; OBSTRUCTION; TOLTERODINE;
D O I
10.1097/MOU.0b013e32831505fe
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Lower urinary tract symptoms (LUTS) include voiding, storage, and postmicturition symptoms whereas in addition LUTS and sexual dysfunction are highly prevalent in aging men. The present article investigates how symptoms can guide our initial therapeutic approach to male LUTS and provides the recent data on the current treatment options. Recent findings Recent studies suggest that not all male LUTS are associated with prostate pathology and that bladder plays a role in the development of LUTS and especially in storage symptoms. In addition to the traditional drug classes including alpha-blockers and 5 alpha-reductase inhibitors, there is an increasing flow of data on the use of anticholinergics and phosphodiesterase type 5 inhibitors. Available studies provide high-level evidence on the efficacy and safety of these medical treatments. The upcoming data are beginning to shape new strategies for the initial management of male LUTS. Summary Male LUTS have a complex nature and there is an overlap of storage and voiding symptoms. Weighing of storage versus voiding symptoms is a decisive factor for the selection of medical treatment. In addition, assessment of specific voiding and prostate parameters and the status of patient's sexual function may guide our choice.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 32 条
[1]   Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction [J].
Abrams, P ;
Kaplan, S ;
Gans, HJD ;
Millard, R .
JOURNAL OF UROLOGY, 2006, 175 (03) :999-1004
[2]   The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002) [J].
Abrams, P ;
Cardozo, L ;
Fall, M ;
Griffiths, D ;
Rosier, P ;
Ulmsten, U ;
Van Kerrebroeck, P ;
Victor, A ;
Wein, A .
UROLOGY, 2003, 61 (01) :37-49
[3]   Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:: A prospective, randomized, controlled study [J].
Athanasopoulos, A ;
Gyftopoulos, K ;
Giannitsas, K ;
Fisfis, J ;
Perimenis, P ;
Barbalias, G .
JOURNAL OF UROLOGY, 2003, 169 (06) :2253-2256
[5]   The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis [J].
Blake-James, Benedict T. ;
Rashidian, Arash ;
Ikeda, Youko ;
Emberton, Mark .
BJU INTERNATIONAL, 2007, 99 (01) :85-96
[6]   Lower urinary tract symptoms revisited: A broader clinical perspective [J].
Chapple, Christopher R. ;
Wein, Alan J. ;
Abrams, Paul ;
Dmochowski, Roger R. ;
Giuliano, Francois ;
Kaplan, Steven A. ;
McVary, Kevin T. ;
Roehrborn, Claus G. .
EUROPEAN UROLOGY, 2008, 54 (03) :563-569
[7]   A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder [J].
Chapple, CR ;
Roehrborn, CG .
EUROPEAN UROLOGY, 2006, 49 (04) :651-659
[8]  
DELAROSETTE J, EAU GUIDELINES BENIG
[10]   Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects [J].
Giuliano, Francois ;
Kaplan, Steven A. ;
Cabanis, Marie-Jose ;
Astruc, Beatrice .
UROLOGY, 2006, 67 (06) :1199-1204